Compare · OMIC vs TXG
OMIC vs TXG
Side-by-side comparison of Singular Genomics Systems Inc. (OMIC) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OMIC and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- TXG is the larger of the two at $8.77B, about 18.0x OMIC ($487.8M).
- TXG has hit the wire 16 times in the past 4 weeks while OMIC has been quiet.
- TXG has more recent analyst coverage (25 ratings vs 5 for OMIC).
- Company
- Singular Genomics Systems Inc.
- 10x Genomics Inc.
- Price
- $19.98+0.35%
- $66.17-1.62%
- Market cap
- $487.8M
- $8.77B
- 1M return
- -
- +13.14%
- 1Y return
- -
- +425.99%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2019
- News (4w)
- 0
- 16
- Recent ratings
- 5
- 25
Singular Genomics Systems Inc.
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest OMIC
- Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)
- Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.
- Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Glezer Eli N. returned 155,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operating Officer Ghai Jyotsna returned 3,283 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Ryan Jason
- Director Pellini Michael J returned 351,222 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Mardis Elaine R
Latest TXG
- Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
- UBS resumed coverage on 10x Genomics with a new price target
- Director Stuelpnagel John R sold $1,235,072 worth of shares (20,000 units at $61.75), decreasing direct ownership by 6% to 328,436 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by 10x Genomics Inc.
- Chief Executive Officer Saxonov Serge gifted 100 shares, decreasing direct ownership by 0.01% to 1,075,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- RBC Capital Mkts initiated coverage on 10x Genomics with a new price target
- Chief Executive Officer Saxonov Serge sold $667,901 worth of shares (10,486 units at $63.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 1,075,349 units (SEC Form 4)
- 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences
- Chief Executive Officer Saxonov Serge sold $1,168,775 worth of shares (18,545 units at $63.02), decreasing direct ownership by 2% to 1,085,835 units (SEC Form 4) to satisfy tax liability